FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Ocugen Inc. Surges After Announcing Binding Letter of Intent with Bharat Biotech”
Ocugen Inc. (NASDAQ: OCGN) shot up over 63% in premarket trading after announcing a binding letter of intent with Bharat Biotech to develop the latter’s COVAXIN vaccine candidate for the United States market.
COVAXIN™ has been evaluated in approximately 1,000 subjects in Phase 1 and Phase 2 clinical trials in India and is currently part of a Phase 3 clinical trial involving 26,000 volunteers.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
For more information, please visit: Sonoma Pharmaceuticals, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.